The pharmaceutical wholesale industry is facing unprecedented challenges. Tariffs, IRA pricing reforms, and new drug legislation are disrupting supply chains, squeezing margins, and forcing wholesalers to rethink their strategies.
What’s at Risk?
- Tariffs may drive up costs on APIs, packaging, and medical devices.
- IRA-driven pricing shifts could reduce reimbursement rates and impact profitability.
- Supply chain vulnerabilities require new sourcing strategies to ensure product availability.
The pharmaceutical landscape is evolving, and those who act now will define the future. Get in-depth insights into how wholesalers can thrive amid market disruptions.
Download the Report
When Security Creates Scarcity: DSCSA’s Unintended Consequence
June 2, 2025
In a recent article, A&M Life Sciences experts discuss The Drug Supply Chain Security Act and how well-intentioned regulations may be straining the very system they’re meant to safeguard.
Medtech CDMOs in 2025: Perspectives on Activity in the Medtech CDMO Market
May 19, 2025
Driving the future of medical innovation, Medtech CDMOs are leveraging strategic M&A and advanced technologies to scale growth. Amid regulatory complexity, key players are accelerating development and meeting rising demand for specialized manufacturing.
Discover the Future of Connected Health
May 2, 2025
Dive into "The Seven Truths of Connected Health," our latest Life Sciences report that explores how connected health changes patient behavior at key decision points.
Elevating Customer Support in Healthcare
April 16, 2025
Customer service isn’t just about solving problems, it’s about shaping perception. In healthcare, where trust and clarity are essential, support teams are uniquely positioned to elevate the entire customer experience.
